WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and...
WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company...
Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value RightsTotal Transaction Value of up to $36 millionTransaction Expected to...
WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company...
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin - - Data to be Presented at the Society for...
- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled - WARREN, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber...
- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc...
- Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI - - Timber has enrolled...
- Treatment with TMB-001 demonstrated greater proportions of participants achieving primary and key secondary endpoints versus vehicle regardless of the subtype of congenital ichthyosis - BASKING...
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ, Feb. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관